ENDP

Endo International plc

ENDP

Market cap $68.8M

Overview Fund Activity

Delisted

ENDP was delisted on the 25th of August, 2022.

Back to rankings

About: Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL. The majority of its revenue comes from the United States.

Employees: 3,103

Healthcare Drug Manufacturers - General

Financial journalist opinion

Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange (NYSE), the two drugmakers said Thursday.

Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing

Drugmaker Endo receives US court approval for bankruptcy restructuring

Bankrupt drugmaker Endo International said on Tuesday a U.S. Bankruptcy Court has approved its restructuring plan and related opioid settlements to emerge from bankruptcy, which began in 2022.

Drugmaker Endo reaches $465 mln bankruptcy settlement with US government

The U.S. Department of Justice said Thursday that it has reached a $465 million settlement with bankruptcy drugmaker Endo International, resolving the federal government's law enforcement, tax, and health care cost claims.

See News Rankings

Charts implemented using Lightweight Charts™